Skip to main content
. 2025 Jun 25. Online ahead of print. doi: 10.1159/000546795

Fig. 1.

Fig. 1.

a Proband’s BMI and HbA1c results during the use of different anti-obesity medication regime. The rating scores of food cravings (scale out of 10), hunger (scale out of 10), and FCQ-T (scale out of 90) were shown. The proband’s continuous glucose profile while on subcutaneous liraglutide 1.8 mg daily (b) and while on subcutaneous semaglutide 2 mg weekly and oral naltrexone-bupropion are shown (c).